Author: Customer Service

DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITALET DU NOMBRE TOTAL DE DROITS DE VOTE AU 28 FEVRIER 2026 Article L. 233-8-II du Code de CommerceArticle 223-16 du Règlement général de l’AMFNombre d’actions composant le capital social 232 848 588Nombre de droits de vote théoriques 254 398 618Nombre de droits de vote exerçables 250 466 446Cette déclaration est en ligne sur le site internet d’Elis www.elis.com DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 28 FEBRUARY 2026Total number of shares 232,848,588Theoretical number of voting rights 254,398,618Number of exercisable voting rights 250,466,446This disclosure is on Elis web site www.elis.com          Contacts Nicolas Buron, Director of Investor Relations, Financing & TreasuryPhone: +33 1 75 49 98 30 –...

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting. This premier annual gathering of neuro‑ophthalmology experts worldwide provides a scientific forefront platform for presenting transformative clinical data amongst leading clinicians, researchers, and thought leaders.As a Platinum Sponsor of the 2026 Congress, Oculis is proud to support the most influential global scientific meeting in neuro‑ophthalmology, reinforcing its commitment to advancing scientific progress in...

ZUG, Switzerland, 16 March, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting. This premier annual gathering of neuro-ophthalmology experts worldwide provides a scientific forefront platform for presenting transformative clinical data amongst leading clinicians, researchers, and thought leaders. As a Platinum Sponsor of the 2026 Congress, Oculis is proud to support the most influential global scientific meeting in neuro-ophthalmology, reinforcing its commitment to advancing scientific progress in this field. NANOS...

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders Date        16 March 2026 Share buyback programme – week 11 The share buyback programme runs in the period 2 February 2026 up to and including 8 May 2026, see company announcement of 30 January 2026. During the period the bank will thus buy back its own shares for a total of up to DKK 500 million under the programme, but to a maximum of 600,000 shares. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the programme...

Today, GN Store Nord A/S (“GN”) has entered into a definitive agreement for the sale of GN’s Hearing business to Amplifon S.p.A. (“Amplifon”), a leading global hearing care retailer. The transaction values the Hearing business at DKK 17.0 billion1 on a cash-free and debt-free basis and will be settled with DKK 12.6 billion2 in cash and 56 million shares in Amplifon. The transaction is subject to customary regulatory approvals and completion of the Hearing business separation from GN and is expected to complete by the end of 2026. Amplifon and GN will together create a global integrated leader in audiology combining hearing technology leadership with high-quality, innovative hearing care to offer comprehensive solutions to both audiology professionals and patients. The combination will create the industry leader in hearing care solutions...

Schindellegi, Switzerland – 16 March 2026 Trifork Group AGCompany announcement no. 19/2026 Weekly report on share buyback On 27 February 2026, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 March 2026 up to and including no later than 31 December 2026. For details, please see company announcement no. 15 of 27 February 2026. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 75 million (approximately EUR 10 million). Under the program, the following transactions have been made:Date                              Number of shares        Average purchase price (DKK)        Transaction value...

Nantes, France, March 16, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026.  Information Date* 2025 Full-Year Financial Update and Statements April 29, 20262026 1Q Cash Position April 30, 2026Annual General Meeting June 24, 20262026 First-Half Financial Update and Statements September 28, 20262026 3Q Cash Position October 27, 20262026 4Q Cash Position January 26, 2027* This financial calendar is provided for information only and may be subject to changes. The Company’s updated financial calendar is available on its corporate website.ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet...